215 related articles for article (PubMed ID: 37704591)
81. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
[TBL] [Abstract][Full Text] [Related]
82. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
Morales AA; Kurtoglu M; Matulis SM; Liu J; Siefker D; Gutman DM; Kaufman JL; Lee KP; Lonial S; Boise LH
Blood; 2011 Aug; 118(5):1329-39. PubMed ID: 21659544
[TBL] [Abstract][Full Text] [Related]
83. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
Vervloessem T; Sasi BK; Xerxa E; Karamanou S; Kale J; La Rovere RM; Chakraborty S; Sneyers F; Vogler M; Economou A; Laurenti L; Andrews DW; Efremov DG; Bultynck G
Cell Death Dis; 2020 Sep; 11(9):769. PubMed ID: 32943617
[TBL] [Abstract][Full Text] [Related]
84. Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.
Bonnefond ML; Lambert B; Giffard F; Abeilard E; Brotin E; Louis MH; Gueye MS; Gauduchon P; Poulain L; N'Diaye M
Apoptosis; 2015 Apr; 20(4):535-50. PubMed ID: 25627260
[TBL] [Abstract][Full Text] [Related]
85. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
86. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
Zhang L; Ramesh P; Steinmetz M; Medema JP
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
[TBL] [Abstract][Full Text] [Related]
87. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
[TBL] [Abstract][Full Text] [Related]
88. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347
[TBL] [Abstract][Full Text] [Related]
89. Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.
Premkumar DR; Jane EP; Thambireddy S; Sutera PA; Cavaleri JM; Pollack IF
Mol Carcinog; 2018 Apr; 57(4):469-482. PubMed ID: 29240261
[TBL] [Abstract][Full Text] [Related]
90. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
Bates DJ; Salerni BL; Lowrey CH; Eastman A
Cancer Biol Ther; 2011 Aug; 12(4):314-25. PubMed ID: 21768777
[TBL] [Abstract][Full Text] [Related]
91. Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.
Richard DJ; Lena R; Bannister T; Blake N; Pierceall WE; Carlson NE; Keller CE; Koenig M; He Y; Minond D; Mishra J; Cameron M; Spicer T; Hodder P; Cardone MH
Bioorg Med Chem; 2013 Nov; 21(21):6642-9. PubMed ID: 23993674
[TBL] [Abstract][Full Text] [Related]
92. ABT-737 is highly effective against molecular subgroups of multiple myeloma.
Bodet L; Gomez-Bougie P; Touzeau C; Dousset C; Descamps G; Maïga S; Avet-Loiseau H; Bataille R; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M
Blood; 2011 Oct; 118(14):3901-10. PubMed ID: 21835956
[TBL] [Abstract][Full Text] [Related]
93. Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-X
Yao W; Bai L; Wang S; Zhai Y; Sun SY
Neoplasia; 2022 Jul; 29():100798. PubMed ID: 35462114
[TBL] [Abstract][Full Text] [Related]
94. MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.
Vikström IB; Slomp A; Carrington EM; Moesbergen LM; Chang C; Kelly GL; Glaser SP; Jansen JH; Leusen JH; Strasser A; Huang DC; Lew AM; Peperzak V; Tarlinton DM
Cell Death Dis; 2016 Aug; 7(8):e2345. PubMed ID: 27560714
[TBL] [Abstract][Full Text] [Related]
95. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
[TBL] [Abstract][Full Text] [Related]
96. The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA.
Muenchow A; Weller S; Hinterleitner C; Malenke E; Bugl S; Wirths S; Müller MR; Schulze-Osthoff K; Aulitzky WE; Kopp HG; Essmann F
Cell Death Dis; 2020 Aug; 11(8):701. PubMed ID: 32839432
[TBL] [Abstract][Full Text] [Related]
97. BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs.
Skwarska A; Konopleva M
Cancer Res; 2023 Nov; 83(21):3501-3503. PubMed ID: 37824434
[TBL] [Abstract][Full Text] [Related]
98. Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.
Melo G; Silva CAB; Hague A; Parkinson EK; Rivero ERC
Oral Oncol; 2022 Sep; 132():105979. PubMed ID: 35816876
[TBL] [Abstract][Full Text] [Related]
99. Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a
Liu T; Lam V; Thieme E; Sun D; Wang X; Xu F; Wang L; Danilova OV; Xia Z; Tyner JW; Kurtz SE; Danilov AV
Clin Cancer Res; 2021 Sep; 27(17):4910-4922. PubMed ID: 34233959
[TBL] [Abstract][Full Text] [Related]
100. Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs.
Ishizawa J; Kojima K; McQueen T; Ruvolo V; Chachad D; Nogueras-Gonzalez GM; Huang X; Pierceall WE; Dettman EJ; Cardone MH; Shacham S; Konopleva M; Andreeff M
PLoS One; 2015; 10(9):e0138377. PubMed ID: 26375587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
